MA50036A - Composés de fluoropipéridine utilisés en tant qu'antagonistes purs du récepteur 5-ht6 - Google Patents
Composés de fluoropipéridine utilisés en tant qu'antagonistes purs du récepteur 5-ht6Info
- Publication number
- MA50036A MA50036A MA050036A MA50036A MA50036A MA 50036 A MA50036 A MA 50036A MA 050036 A MA050036 A MA 050036A MA 50036 A MA50036 A MA 50036A MA 50036 A MA50036 A MA 50036A
- Authority
- MA
- Morocco
- Prior art keywords
- dementia
- alkyl
- disease
- represents hydrogen
- halo
- Prior art date
Links
- MTJLFBYYTSWTBO-UHFFFAOYSA-N 1-fluoropiperidine Chemical class FN1CCCCC1 MTJLFBYYTSWTBO-UHFFFAOYSA-N 0.000 title abstract 3
- 108091005435 5-HT6 receptors Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 230000000155 isotopic effect Effects 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000050060 5-Hydroxytryptamine 6 receptors Human genes 0.000 abstract 1
- 108700039170 5-Hydroxytryptamine 6 receptors Proteins 0.000 abstract 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 abstract 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 abstract 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000009829 Lewy Body Disease Diseases 0.000 abstract 1
- 201000002832 Lewy body dementia Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000024571 Pick disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 201000004810 Vascular dementia Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000009245 menopause Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des composés de fluoropipéridine de formule (i), leurs stéréoisomères, leurs formes isotopiques ou leurs sels pharmaceutiquement acceptables en tant qu'antagonistes du récepteur 5-ht6. La présente invention concerne particulièrement les procédés de préparation, la composition pharmaceutique, les combinaisons et l'utilisation des composés de fluoropipéridine, leurs stéréoisomères, leurs formes isotopiques ou leurs sels pharmaceutiquement acceptables. Dans la formule (i), r1 représente phényle ou pyridyle; le phényle ou le pyridyle étant éventuellement substitué par un ou plusieurs groupes choisis parmi halogène, alkyle en (c1-6) ou alkyle halo (c1-6 ); r2 représente hydrogène ou alkyle en (c1-6); r3 représente hydrogène ou alkyle en (c1-6); ou r2 et r3 peuvent se combiner ensemble pour former un cycloalkyle en (c3-6); r4 représente hydrogène, alkyle en (c1-6) ou alkyle halo (c1-6); r5 représente hydrogène, alkyle en (c1-6), alkyle halo (c1-6) ou cycloalkyle -(ch2)0 -3- (c3-6). Les composés peuvent être utilisés dans le traitement d'un trouble cognitif induit par le récepteur 5-hydroxytryptamine 6, ledit trouble cognitif étant choisi dans le groupe constitué par la démence dans la maladie d'alzheimer, la démence dans la maladie de parkinson, la démence dans la maladie de huntington, la démence associée au syndrome de down, la démence associée au syndrome de tourette, la démence associée à la ménopause, la démence frontotemporale, la démence à corps de lewy, la démence vasculaire, la démence en vih, la démence dans la maladie de creutzfeldt-jakob, la démence persistante induite par une substance, la démence dans la maladie de pick, la démence dans la schizophrénie, la démence dans des conditions médicales générales et la démence sénile.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201741028024 | 2017-08-07 | ||
| PCT/IB2018/055894 WO2019030641A1 (fr) | 2017-08-07 | 2018-08-06 | Composés de fluoropipéridine utilisés en tant qu'antagonistes purs du récepteur 5-ht 6 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA50036A true MA50036A (fr) | 2020-05-13 |
| MA50036B1 MA50036B1 (fr) | 2021-06-30 |
Family
ID=63678636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA50036A MA50036B1 (fr) | 2017-08-07 | 2018-08-06 | Composés de fluoropipéridine utilisés en tant qu'antagonistes purs du récepteur 5-ht6 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10973831B2 (fr) |
| EP (1) | EP3649124B1 (fr) |
| JP (1) | JP6808088B2 (fr) |
| KR (1) | KR102190332B1 (fr) |
| CN (1) | CN111051302B (fr) |
| AU (1) | AU2018313049B2 (fr) |
| BR (1) | BR112020002227A2 (fr) |
| CA (1) | CA3071084C (fr) |
| CY (1) | CY1124174T1 (fr) |
| DK (1) | DK3649124T3 (fr) |
| EA (1) | EA202090397A1 (fr) |
| ES (1) | ES2874628T3 (fr) |
| HR (1) | HRP20210822T1 (fr) |
| HU (1) | HUE055186T2 (fr) |
| IL (1) | IL272287B (fr) |
| LT (1) | LT3649124T (fr) |
| MA (1) | MA50036B1 (fr) |
| MD (1) | MD3649124T2 (fr) |
| MX (1) | MX2020001311A (fr) |
| PL (1) | PL3649124T3 (fr) |
| PT (1) | PT3649124T (fr) |
| RS (1) | RS61886B1 (fr) |
| SG (1) | SG11202000833YA (fr) |
| SI (1) | SI3649124T1 (fr) |
| SM (1) | SMT202100305T1 (fr) |
| WO (1) | WO2019030641A1 (fr) |
| ZA (1) | ZA202000758B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3976581T3 (da) * | 2019-05-24 | 2024-01-22 | Irl 790 Ab | Tartaric acid salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1562918B1 (fr) * | 2002-11-08 | 2008-01-16 | F. Hoffmann-La Roche Ag | Benzoxazinones substitues et utilisations associees |
| ES2232292B1 (es) * | 2003-07-30 | 2006-11-01 | Laboratorios Del Dr. Esteve, S.A. | Compuestos sulfonamidicos derivados de benzoxazinona, su preparacion y uso como medicamentos. |
| US7378415B2 (en) | 2004-09-30 | 2008-05-27 | Roche Palo Alto Llc | Benzoxazine and quinoxaline derivatives and uses thereof |
| US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| ES2348467T3 (es) * | 2004-09-30 | 2010-12-07 | F. Hoffmann-La Roche Ag | Derivados y usos de la benzoxazina y la quinoxalina. |
| ATE477248T1 (de) * | 2004-09-30 | 2010-08-15 | Hoffmann La Roche | Benzoxazin- und chinoxalinderivate und anwendungen |
| JP2008037850A (ja) * | 2006-08-10 | 2008-02-21 | Mitsubishi Tanabe Pharma Corp | 新規置換ピペリジン誘導体 |
-
2018
- 2018-08-06 SI SI201830293T patent/SI3649124T1/sl unknown
- 2018-08-06 JP JP2020505814A patent/JP6808088B2/ja active Active
- 2018-08-06 AU AU2018313049A patent/AU2018313049B2/en active Active
- 2018-08-06 MX MX2020001311A patent/MX2020001311A/es unknown
- 2018-08-06 SG SG11202000833YA patent/SG11202000833YA/en unknown
- 2018-08-06 CN CN201880056542.7A patent/CN111051302B/zh active Active
- 2018-08-06 PL PL18773832T patent/PL3649124T3/pl unknown
- 2018-08-06 KR KR1020207004769A patent/KR102190332B1/ko active Active
- 2018-08-06 MD MDE20200518T patent/MD3649124T2/ro unknown
- 2018-08-06 EA EA202090397A patent/EA202090397A1/ru unknown
- 2018-08-06 SM SM20210305T patent/SMT202100305T1/it unknown
- 2018-08-06 PT PT187738323T patent/PT3649124T/pt unknown
- 2018-08-06 ES ES18773832T patent/ES2874628T3/es active Active
- 2018-08-06 CA CA3071084A patent/CA3071084C/fr active Active
- 2018-08-06 DK DK18773832.3T patent/DK3649124T3/da active
- 2018-08-06 WO PCT/IB2018/055894 patent/WO2019030641A1/fr not_active Ceased
- 2018-08-06 US US16/635,893 patent/US10973831B2/en active Active
- 2018-08-06 HR HRP20210822TT patent/HRP20210822T1/hr unknown
- 2018-08-06 BR BR112020002227-6A patent/BR112020002227A2/pt active Search and Examination
- 2018-08-06 HU HUE18773832A patent/HUE055186T2/hu unknown
- 2018-08-06 EP EP18773832.3A patent/EP3649124B1/fr active Active
- 2018-08-06 MA MA50036A patent/MA50036B1/fr unknown
- 2018-08-06 LT LTEP18773832.3T patent/LT3649124T/lt unknown
- 2018-08-06 RS RS20210640A patent/RS61886B1/sr unknown
-
2020
- 2020-01-27 IL IL272287A patent/IL272287B/en unknown
- 2020-02-05 ZA ZA2020/00758A patent/ZA202000758B/en unknown
-
2021
- 2021-05-25 CY CY20211100449T patent/CY1124174T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51530B1 (fr) | Composés cycliques fondus | |
| MA58181B1 (fr) | Composés tricycliques substitués | |
| MA41338B1 (fr) | Composés de pyrazine pour le traitement de maladies infectieuses | |
| MA45888A1 (fr) | Inhibiteurs de tyrosine kinase de bruton | |
| MA42239B1 (fr) | Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| MA38079A1 (fr) | Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés | |
| MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA34898B1 (fr) | Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques | |
| MA29335B1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
| TN2015000547A1 (fr) | Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1 | |
| MA45222A (fr) | Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA46038A (fr) | Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale | |
| MA38227A1 (fr) | Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase | |
| MA33450B1 (fr) | Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques | |
| MA31373B1 (fr) | Composes amino-heterocycliques | |
| MA27990A1 (fr) | Derives de piperazine pour le traitement d'infections par le vih | |
| KR102717545B1 (ko) | 기생충성 질환의 치료를 위한 화합물 및 방법 | |
| MA27775A1 (fr) | Composes organiques | |
| WO2019007696A1 (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| MA35286B1 (fr) | Phényl-3-aza-bicyclo[3.1.0]hex-3-yl-méthanones et leur utilisation en tant que médicament | |
| CR20200584A (es) | Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes | |
| MA41633A (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| PE20221020A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1 | |
| MA54447B1 (fr) | Dérivés de 7-phénoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine et composés similaires en tant que modulateurs de la secretase gamma pour le traitement de la maladie d'alzheimer | |
| MA41494B1 (fr) | Composés benzoxaborole substitués en position 4 et utilisations associées |